Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects

Inclusion Criteria: * Healthy adult aged ≥19 to \<50 years at the time of screening tests * Body mass index(BMI) of ≥18.0 kg/m2 to ≤27.0 kg/m2, with body weight of ≥55.0 kg to ≤90.0 kg for men and ≥50.0 kg to ≤90.0 kg for women at the time of screening tests * Determined by the investigator to be eligible for study participation based on the results of screening tests * Intact deltoid muscle that allows administration of the investigational product * Consent to use medically acceptable contraception throughout the study * Negative finding from a pregnancy test (urine hCG) at the time of the screening for women of childbearing potential * Voluntary decision and provision of written consent on participation in this study Exclusion Criteria: * History of a hand-foot-mouth disease or history of a disease related with enterovirus(EV) infection within 3 months prior to the 1st IP administration * Medical history of an anaphylactic or similar acute reaction to IN-B001 or similar vaccine * Febrile disease or infectious disease within 2 weeks prior to the 1st IP administration * Whole blood donation within 2 months or apheresis within 1 month prior to the 1st IP administration * Vaccination with other prevention vaccine within 2 months prior to the 1st IP administration * Use of an immunomodulator or immunosuppressant within 3 months prior to the 1st IP administration * History of a Guillain Barre syndrome * Excessive caffeine intake or continuous alcohol consumption or incapable of abstention from alcohol during the study * Participation in other clinical trial within 6 months prior to the 1st IP administration * Pregnant or breastfeeding women * Clinically significant hepatic, renal, neurological, respiratory, endocrine, hematology and oncology, cardiovascular, urological or psychiatric disease or such history * Positive serological finding (type B hepatitis test, type C hepatitis test, human immunodeficiency virus(HIV) test) * History of drug abuse or positive finding from a urine screening test for an abusive drug * Use or of any prescription medication or oriental medicine within 2 weeks or any over-the-counter(OTC) medication, health functional food or vitamin within 1 week prior to the 1st IP administration or expected use of such products * Administration of a blood product or blood-derived agent within 3 months prior to the 1st IP administration * Determined by the investigator to be ineligible for study participation due to other reason including clinical laboratory findings